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ABSTRACT
Tumour necrosis factor-alpha (TNF-a), interleukin (IL)-6, -8 and-10 and soluble TNF receptor II (sTNFR
II) levels were measured at baseline, and after antifungal therapy for 2 weeks and 3 months, in plasma
from 75 human immunodeﬁciency virus (HIV)-positive and 14 HIV-negative patients with cryptococ-
cosis, and in plasma from 14 HIV-positive controls. At baseline, TNF-a, IL-6 and sTNFR II levels, and
cryptococcal antigen titres, were increased in patients with fungaemia compared to controls (p < 0.02).
The mediator levels were not inﬂuenced by the severity of the disease or subsequent death, but sTNFR II
and IL-10 levels were reduced, together with virus load, in patients receiving anti-retroviral agents
(p < 0.01). During antifungal therapy, sTNFR II levels decreased (p 0.003) in parallel with the virus load
and with an increase in CD4 T-cell numbers.
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INTRODUCTION
Cryptococcus neoformans infection usually occurs in
patients infected by human immunodeﬁciency
virus (HIV), for whom fungaemia has been
associated with a poor prognosis [1]. It is known
that human mononuclear cells or neutrophils are
able to produce pro-inﬂammatory and anti-
inﬂammatory cytokines in vitro in the presence
of intact C. neoformans or its components [2,3]. It
has also been shown that HIV infection can
reduce the anti-cryptococcal activity of human
peripheral blood mononuclear cells, or their
capacity to produce cytokines in the presence of
C. neoformans [4], and that HIV type-1 envelope
glycoprotein 120 alters the T-cell response to the
yeast [5]. In addition, the inﬂuence of C. neofor-
mans, or its antigens, on the replication of HIV has
been documented [6]. In mice, Th1 cytokines and
tumour necrosis factor-alpha (TNF-a) have been
shown to have important roles in host defence
against C. neoformans [7].
To determine whether an overall immunologi-
cal response is associated with C. neoformans
fungaemia, sequential plasma concentrations of
pro-inﬂammatory and anti-inﬂammatory cytok-
ines and mediators were measured in adults with
culture-conﬁrmed cryptococcosis. The inﬂuence
of HIV infection and its treatment on this
response were then evaluated, and the question
of whether the levels of these mediators reﬂected
the severity of cryptococcal disease was investi-
gated.
PATIENTS AND METHODS
Study design and patients
The present study was part of an ongoing prospective
multicentre study initiated at the National Reference Centre
for Mycoses (NRCM) in France (Crypto A ⁄D study). Patients
were aged > 18 years and anonymity was respected as
required by the ‘Commission Nationale Informatique et
Liberte´’. All patients, or their relatives in cases with abnormal
mental status, gave informed consent. Patients were included
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if at least one culture yielded C. neoformans and this was the
ﬁrst episode of cryptococcosis. Biological samples were
obtained at baseline (D0), and after antifungal therapy for 2
and 12 weeks. The study protocol was approved by the Ethics
Committee of the Groupe Hospitalier Necker-Enfants Ma-
lades, Paris, France (DGS 970089, French Ministry of Health).
Deﬁnitions
Meningitis was deﬁned as isolation of C. neoformans from the
cerebrospinal ﬂuid. Dissemination was deﬁned as the isolation
of C. neoformans from at least two non-contiguous sites.
Patients were considered to have a poor prognosis on the
basis of abnormal mental status, palsies or seizures. Overall
mortality after 3 months was recorded.
Sample processing and cytokine immunoassays
Plasma samples were frozen for storage within a few hours of
sampling. Upon thawing, they were used immediately for
TNF-a and interleukin-10 (IL-10) measurements, and then
aliquoted and refrozen at )70C. Pro-inﬂammatory (TNF-a,
IL-6, IL-8) and anti-inﬂammatory (IL-10, soluble TNF receptor
II (sTNFR II)) mediator concentrations were assessed by ELISA
(R & D Systems, Abingdon, UK). Sequential samples from a
given patient were tested simultaneously. Concentrations were
determined by comparison with standard curves. According to
the thresholds established by the manufacturer and the
dilution used, the minimum detectable levels were 4.4 pg ⁄mL
for TNF-a, 0.7 pg ⁄mL for IL-6, 10 pg ⁄mL for IL-8, 2 pg ⁄mL for
IL-10, and 20 pg ⁄mL for sTNFR II.
Statistical analysis
Statistical analyses were performed with Epi Info v. 6.0
(Centers for Disease Control, Atlanta, GA, USA) and Graph
Pad Prism v. 3.0.3 (Graph Pad Software, San Diego, CA, USA).
Mediator levels were compared using the Mann–Whitney
U-test or Kruskal–Wallis test, depending on the number of
groups. The Spearman test was used to establish correlations
between cytokines and other parameters. The Wilcoxon rank
test was used for the kinetics analysis. Signiﬁcance was
deﬁned as p < 0.05.
RESULTS
Characteristics of the study population and
controls
The study population consisted of 75 HIV-posit-
ive patients, while the controls consisted of 14
HIV-positive patients (nine males and ﬁve
females) with an evolving HIV infection, but
without concomitant opportunistic infection or
malignancy at the time of sampling. The charac-
teristics of the controls did not differ from those of
patients with cryptococcosis (median age,
38.5 years (range 33–68 years); median CD4+
T-lymphocytes ⁄mm3, 38 (range 1–304); median
(log10) plasma virus load, 5.2 (range 4.1–5.6)).
Additional controls were 14 HIV-negative
patients with evolving cryptococcosis (Table 1).
At the time of diagnosis, 27 patients had been
receiving anti-retroviral therapy, including 20
patients receiving highly active anti-retroviral
therapy, for a median duration of 9 months
(range 1–36 months). Serum cryptococcal antigen
titres were signiﬁcantly higher in patients with
fungaemia than in those without fungaemia
(median log2 reciprocal titre, 11 (range 2–21) vs.
8 (range 3–20); p 0.005). Nine patients died,
including four patients who died as a result of
clinically and mycologically active cryptococcosis.
Inﬂuence of host characteristics on the baseline
cytokine response during cryptococcosis
Low baseline plasma levels of all mediators
except sTNFR II were observed (Table 1). TNF-a,
sTNFR II and IL-6 concentrations were higher in
HIV-positive patients with cryptococcosis than in
seronegative patients, while levels of the other
mediators were similar. In HIV-infected patients,
none of the cytokine levels correlated with CD4
cell counts or virus load, and baseline levels of
sTNFR II and IL-10 were signiﬁcantly lower in
those patients receiving anti-retroviral drugs than
Table 1. Baseline characteristics of HIV-infected and HIV-
negative patients with cryptococcosis
Parameter
studied
HIV-positive
patients (n = 75)
HIV-negative
patients (n = 14)
Male : female ratio 9.7:1 3.7:1
Age in years, median (range) 37 (26–63) 50 (28–71)
Caucasian, % 65 86
CD4+ lymphocytes ⁄mm3,
median (range)
21 (0–480) 188 (22–490)
Log10 plasma viral load, median (range) in:
Patients receiving anti-retroviral
treatment (n = 27)
4.5 (0.8–6.3) –
Patients without anti-retroviral
treatment (n = 48)
5.2 (3.4–6.4)a –
Fever (‡ 38C), % 67 57
Meningitis, % 83 64
Dissemination, % 67 50
Fungaemia, % 53 14
Signs of poor prognosis, % 43 50
Body mass index, median (range) 20.1 (13–30) 22.4 (16–29)
Leukocytes, median
(range) · 103 ⁄mm3
4.5 (1–16.6) 7 (1.6–45)
Serum antigen titre, reciprocal log2 10 (2–21) 6 (2–13)
Concentrations of mediators in plasma, median (range)
TNF-a 4.4 (4.4–924)a 4.4 (4.4–10)
IL-6 11.2 (0.7–610)a 5.6 (0.7–28.9)
IL-8 16.1 (10–874) 18.9 (10–268)
IL-10 5.8 (2–99.4) 4.3 (2–20.8)
sTNFR II 5757 (2580–11400)b 3830 (1738–8566)
ap < 0.05; bp < 0.01.
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in untreated patients (median 4365 pg ⁄mL
(range 3122–9560) vs. 6340 pg ⁄mL (range 2580–
1400), p < 0.01; and 2.9 pg ⁄mL (range 2–99) vs.
8.3 pg ⁄mL (range 2–74), p < 0.003), while TNF-a,
IL-6 and IL-8 levels did not differ signiﬁcantly
(data not shown).
Only baseline sTNFR II concentrations were
signiﬁcantly higher in male than in female
patients infected with HIV (median 5931 pg ⁄mL
(range 2580–1400) vs. 3620 pg ⁄mL (range 3160–
5260), respectively, p 0.0017).
Inﬂuence of cryptococcosis characteristics
on the baseline cytokine response in HIV-
positive patients
Patients for whom the interval between the ﬁrst
clinical symptoms and the start of antifungal
therapy was ‡ 8 days had higher concentra-
tions of IL-8 than those for whom this inter-
val was shorter (median 20 pg ⁄mL (range
10–874) vs. 10 pg ⁄mL (range 10–326), respect-
ively; p 0.0043).
Baseline TNF-a, IL-6 and sTNFR II concentra-
tions were signiﬁcantly higher in patients with
fungaemia (Fig. 1) or dissemination (data not
shown) than in patients without fungaemia and
in controls, while IL-8 and IL-10 concentrations
did not differ between the four groups (data not
shown). The presence of meningitis, poor prog-
nostic clinical factors at diagnosis, subsequent
death, or the precise infecting serotype, were not
associated with changes in the plasma levels of
the mediators. There was no correlation between
antigen titres and any of the markers measured
(data not shown).
Kinetics of mediators in the plasma of
HIV-positive patients with initial fungaemia
caused by C. neoformans
sTNFR II levels decreased signiﬁcantly between
week 2 and month 3 in the 24 patients for whom
samples were available at the three sampling
times. No signiﬁcant differences according to the
date of sampling were observed for the other
parameters measured. In parallel, between the
day 0 and month 3 samples, all the patients tested
received highly active anti-retroviral therapy,
resulting in a signiﬁcant decrease in the virus
load, and a signiﬁcant increase in the CD4 cell
count (Fig. 2).
DISCUSSION
Previous studies on the cytokine response in
humans with cryptococcosis were focused mostly
on patients with meningitis [8,9]. The presence of
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Fig. 1. Biological parameters at baseline in the serum of
HIV-positive patients with (HIV+, blood+, n = 40) or
without (HIV+, blood–, n = 35) fungaemia, 14 HIV-negat-
ive (HIV–, blood+ ⁄ –) patients, all with cryptococcosis, and
14 HIV-positive controls without cryptococcosis (HIV+
controls). Data are shown as boxes: internal horizontal
lines, medians; tops and bottoms of boxes, 25th and 75th
percentiles, respectively; upper and lower bars, 10th and
90th percentiles, respectively. Kruskal–Wallis test: (A)
tumour necrosis factor-alpha (TNF-a) concentrations,
p < 0.001; (B) interleukin-6 (IL-6) concentrations, p < 0.02;
(C) soluble TNF receptor II (sTNFR II) concentrations,
p < 0.0002.
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viable C. neoformans in the cerebrospinal ﬂuid of
HIV-positive patients was associated with signi-
ﬁcantly higher local production of TNF-a ⁄ sTNFR
II, IL-6 and IL-8. Preliminary data suggested that
the cytokine response in plasma might reﬂect
dissemination of the infection in HIV-positive
patients [10]. Clear differences in the immune
response have also been demonstrated previously
between the cerebral and blood compartments
during experimental disseminated cryptococcosis
[10]. The present study therefore studied pro-
spectively the dynamics of the pro-inﬂammatory
and anti-inﬂammatory cytokine responses in the
plasma of a large cohort of HIV-infected or
seronegative patients with cryptococcosis in rela-
tion to the presence of fungaemia and host
characteristics. Higher levels of TNF-a ⁄ sTNFR II
and IL-6 were observed in the plasma of HIV-
positive patients with fungaemia than in controls.
Interestingly, dose-dependent secretion of cytok-
ines has been shown using cells stimulated by
cryptococcal antigen [2], which is in agreement
with the present ﬁndings, since patients with
fungaemia had higher antigen titres. In addition,
in a murine model of haematogenous dissemin-
ated cryptococcosis, a clear correlation was found
between the magnitude of fungaemia and the
production of mediators [10].
The fact that fungaemia did not inﬂuence IL-8
production in HIV-infected patients is in accord-
ance with the impaired ability to produce IL-8 in
the presence of C. neoformans exhibited by neu-
trophils from HIV-infected patients with low CD4
cell counts compared to controls [11]. More
recently, it has been shown that the mannopro-
tein-4 (MP-4) of C. neoformans is able to stimulate
the production of sTNFR II by human neutrophils
[12]. Knowing that MP-4 has been detected in the
serum of patients with disseminated cryptococ-
cosis, it is tempting to speculate that the higher
concentrations of sTNFR II measured during
cryptococcaemia might be related to increased
serum concentrations of MP-4 in fungaemic
patients.
C. neoformans andHIV, or their treatments, could
have additional interactions. C. neoformans has
been shown to enhance HIV expression in mono-
cytic cells through a TNF-a-dependent mechanism
[4]. In addition, it was observed that the prescrip-
tion of anti-retroviral therapy at baseline was
associated with signiﬁcantly reduced levels of
sTNFR II and IL-10, in parallel with a signiﬁcant
reduction in the HIV load. Pietrella et al. [5] have
shown in vitro that glycoprotein gp120 of HIV
type-1 induced the development of a T-helper
type-2-dominant response to C. neoformans. The
decreased IL-10 levels observed following the
control of HIV load in patients treated with anti-
retroviral agents may be of importance for the
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Fig. 2. Kinetics of plasma soluble TNF receptor II (sTNFR
II), virus load and CD4 cell count from day 0 (D0) to week
2 (W2) and month 3 (M3) of antifungal therapy in human
immunodeﬁciency virus (HIV)-positive patients with cryp-
tococcaemia: sTNFR II, n = 24; virus load, n = 16; CD4 cell
count, n = 20. sTNFR II data are shown as boxes: internal
horizontal lines, medians; tops and bottoms of boxes, 25th
and 75th percentiles, respectively; upper and lower bars,
10th and 90th percentiles, respectively. Virus load and CD4
cell counts are presented as individual values, with the line
representing the median value at both times. Wilcoxon-
rank test: (A) sTNFR II concentrations between W2 and
M3, p 0.003; (B) CD4 cell counts between D0 and M3,
p < 0.0001; (C) virus load between D0 and M3, p < 0.02.
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subsequent control of cryptococcosis. Indeed,
gp120 exacerbates the capability of C. neoformans
to induce IL-10 by monocytes [13].
The administration of anti-retroviral agents is
known to improve, or even normalise, the anti-
cryptococcal activity of leukocytes in vitro [14]. In
the present study, the prescription of anti-retro-
viral agents was associated with a signiﬁcant
reduction in virus load and sTNFR II plasma
levels, and also with an increase in the number of
CD4 T-lymphocytes following antifungal therapy
for 3 months. Thus, the data conﬁrm that sTNFR
II is relevant for the management of HIV-infected
patients in the context of cryptococcosis, since it is
linked strongly to immunological and virological
parameters associated with HIV infection [15].
In conclusion, this study, which focused on the
immune response observed in the blood compart-
ment in humans with cryptococcosis, demonstra-
ted that the presence of viable yeasts, or their
products, and of HIV, inﬂuenced the pro-inﬂam-
matory and anti-inﬂammatory responses. In addi-
tion, other parameters, such as the site and
severity of the fungal infection, the gender of
the host, and the control measures for HIV
infection, can also contribute to the modulation
of the immune response during cryptococcosis.
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